(0.33%) 5 116.80 points
(0.33%) 38 367 points
(0.37%) 15 987 points
(-0.94%) $83.06
(5.25%) $2.02
(0.35%) $2 355.30
(0.54%) $27.69
(4.12%) $960.05
(-0.27%) $0.932
(-0.46%) $10.97
(-0.57%) $0.796
(1.66%) $93.40
@ $1.749
発行日: 10 2月 2024 @ 00:59
リターン: 59.90%
前回のシグナル: 2月 9 - 05:16
前回のシグナル:
リターン: 5.05 %
Live Chart Being Loaded With Signals
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients...
Stats | |
---|---|
本日の出来高 | 23 569.00 |
平均出来高 | 1.12M |
時価総額 | 73.53M |
EPS | $0 ( 2024-04-09 ) |
次の収益日 | ( $-0.250 ) 2024-06-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.780 |
ATR14 | $0.0330 (1.17%) |
ボリューム 相関
Lava Therapeutics B.V. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Lava Therapeutics B.V. 相関 - 通貨/商品
Lava Therapeutics B.V. 財務諸表
Annual | 2023 |
収益: | $6.77M |
総利益: | $3.29M (48.56 %) |
EPS: | $-1.570 |
FY | 2023 |
収益: | $6.77M |
総利益: | $3.29M (48.56 %) |
EPS: | $-1.570 |
FY | 2022 |
収益: | $19.39M |
総利益: | $19.39M (100.00 %) |
EPS: | $-1.230 |
FY | 2021 |
収益: | $5.00M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.30 |
Financial Reports:
No articles found.
Lava Therapeutics B.V.
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。